Sildenafil citrate is the citrate salt form of sildenafil. The phrase does not identify a second therapeutic medicine: sildenafil remains the pharmacologically active drug moiety, while citrate is the counterion present in the pharmaceutical salt.
This distinction explains why product information can use both terms. A label may identify the drug substance as sildenafil citrate while describing a tablet, suspension or other product in terms of the amount of sildenafil that the citrate salt provides.
This page explains how the salt name, active-moiety name and label-strength expression fit together. It also distinguishes the core pharmacology of sildenafil from the physicochemical and formulation role of using sildenafil as a citrate salt.
Sildenafil citrate is a pharmaceutical salt formed from sildenafil and citrate. Official product descriptions identify sildenafil medicines as containing the citrate salt even when the product strength is expressed simply as an equivalent amount of sildenafil.
Salt formation is a standard pharmaceutical concept in which an ionizable drug is paired with a counterion to create a defined drug substance. In this case, sildenafil provides the pharmacologically active moiety and citrate forms the accompanying salt component.
The name sildenafil citrate therefore describes chemical form rather than a separate therapeutic identity. It does not create another drug class, indication or molecular target distinct from sildenafil.
| Term | Meaning |
|---|---|
| Sildenafil | Pharmacologically active drug moiety |
| Citrate | Counterion associated with the pharmaceutical salt |
| Sildenafil citrate | Defined citrate salt form containing the sildenafil moiety |
The term active moiety is used to distinguish the pharmacologically relevant part of a drug substance from attached portions such as the counterion in a salt. For sildenafil citrate, the sildenafil portion is the moiety responsible for the drug's characteristic PDE5-inhibitor pharmacology.
Citrate is chemically part of the complete salt form, but it is not a second PDE5 inhibitor and does not provide a separate therapeutic mechanism alongside sildenafil. This is why clinical pharmacology sections describe the actions and plasma concentrations of sildenafil rather than treating citrate as a second active drug.
Separating active moiety from salt form is also important when interpreting product strength. A medicine can physically contain sildenafil citrate while its labeled strength is expressed according to the corresponding amount of sildenafil.
| Component | Role |
|---|---|
| Sildenafil | Provides the drug's core pharmacological activity |
| Citrate | Counterion forming the citrate salt |
| PDE5 inhibition | Pharmacological action attributable to sildenafil |
A pharmaceutical salt is a defined chemical form created when an ionizable drug substance is paired with an appropriate oppositely charged component. Salt formation is widely used in pharmaceutical development because it can influence practical properties of a drug substance without changing the identity of the pharmacologically active moiety.
Properties such as crystallinity, handling, stability and solubility can depend on the chemical form used in a pharmaceutical product. For sildenafil citrate, current product descriptions characterize the salt as a crystalline drug substance with a molecular weight of approximately 666.7.
Those pharmaceutical properties should be distinguished from mechanism of action. The use of a citrate salt can matter for the physical drug substance and formulation, while PDE5 inhibition remains attributable to sildenafil.
| Concept | Meaning |
|---|---|
| Drug moiety | Pharmacologically relevant part of the drug substance |
| Counterion | Oppositely charged component paired with the drug moiety |
| Salt form | Defined chemical form containing the drug moiety and counterion |
| Sildenafil citrate molecular weight | Approximately 666.7 |
Sildenafil and sildenafil citrate should not be treated as two unrelated medicines competing in a head-to-head comparison. Sildenafil names the active drug moiety, whereas sildenafil citrate identifies the citrate salt containing that same sildenafil moiety.
The difference matters when reading chemistry, manufacturing and product-description information, but it does not mean that a patient is receiving two different PDE5-inhibitor drugs. The therapeutic pharmacology still centers on sildenafil.
A useful way to interpret the terminology is to think in layers: sildenafil identifies the active drug, sildenafil citrate identifies its pharmaceutical salt form, and the final tablet, suspension or other dosage form identifies the medicine product in which that salt is supplied.
| Term | Best Interpretation |
|---|---|
| Sildenafil | Active-drug or active-moiety name |
| Sildenafil citrate | Citrate salt-form name |
| Different therapeutic drugs? | No |
| Different pharmaceutical terminology levels? | Yes |
Drug labeling often needs to describe both the chemical drug substance present in the product and the amount of pharmacologically active moiety represented by that substance. Sildenafil labels therefore commonly use sildenafil citrate in ingredient or description sections while expressing product strength as an equivalent quantity of sildenafil.
For example, current tablet labeling can state that a product contains sildenafil citrate equivalent to a specified amount of sildenafil. The strength printed for the medicine therefore refers to sildenafil-equivalent content rather than requiring the user to interpret the total mass of the citrate salt.
This explains why the words sildenafil and sildenafil citrate can legitimately appear in different parts of the same product information. The wording changes according to whether the label is discussing chemical identity, ingredient form or represented active-drug strength.
| Label Layer | Possible Terminology |
|---|---|
| Drug substance | Sildenafil citrate |
| Active-moiety expression | Sildenafil |
| Product strength | Amount expressed as sildenafil equivalent |
| General drug reference | Sildenafil |
The complete sildenafil citrate salt contains both the sildenafil moiety and citrate, so the mass of the entire salt is greater than the mass represented by sildenafil alone. Product labeling deals with this distinction by stating how much sildenafil the citrate-containing drug substance represents.
For conventional sildenafil tablets, labels commonly describe the formulation as containing sildenafil citrate equivalent to 25 mg, 50 mg or 100 mg of sildenafil. In another formulation example, oral-suspension labeling can describe a quantity of sildenafil citrate and state the corresponding sildenafil-equivalent amount.
The word equivalent therefore refers to active-moiety expression, not to the presence of two active medicines. It allows strengths from citrate-containing products to be communicated consistently in terms of sildenafil.
| Expression | Meaning |
|---|---|
| Sildenafil citrate | Complete pharmaceutical salt |
| Equivalent amount of sildenafil | Amount represented as the active sildenafil moiety |
| Tablet strength | Typically communicated in sildenafil-equivalent terms |
| Two active drugs present | No |
The mass of sildenafil citrate includes the sildenafil portion plus the citrate component of the salt. For that reason, a given mass of sildenafil citrate cannot be interpreted as the same mass of sildenafil active moiety on a one-to-one basis.
Current drug descriptions list a molecular weight of approximately 666.7 for sildenafil citrate. This chemical property helps explain why a product containing enough citrate salt to provide a stated amount of sildenafil necessarily contains a greater total mass of drug substance than the sildenafil-equivalent strength alone.
In routine use, however, readers do not need to calculate that conversion themselves. Regulated product information specifies the represented sildenafil amount, and that labeled expression should be used instead of attempting to infer product strength from raw salt mass.
| Mass Concept | Includes |
|---|---|
| Sildenafil moiety mass | Mass attributed to the sildenafil portion |
| Sildenafil citrate salt mass | Mass of sildenafil together with the citrate component |
| Product strength expression | Amount represented as sildenafil according to the label |
The core pharmacological mechanism is attributed to sildenafil. After systemic availability, sildenafil inhibits PDE5 and thereby modifies cGMP breakdown; calling the original drug substance sildenafil citrate does not create a separate molecular target.
That does not mean the choice of salt form is pharmaceutically meaningless. A salt form can affect properties relevant to manufacturing and formulation, but those physicochemical considerations should be distinguished from the core pharmacodynamic mechanism of the active sildenafil moiety.
The mechanism itself is explained in plain language on the how sildenafil works page.
| Mechanism Question | Answer |
|---|---|
| What inhibits PDE5? | Sildenafil |
| Does citrate create another PDE5 target? | No |
| Can salt form matter for pharmaceutical properties? | Yes |
| Does salt terminology define a separate pharmacological mechanism? | No |
No. Sildenafil remains a phosphodiesterase type 5 inhibitor whether a source uses the shorter active-drug name sildenafil or the complete salt-form name sildenafil citrate.
Drug class follows the pharmacologically active moiety and its mechanism. The presence of citrate in the pharmaceutical salt does not create another therapeutic class or move the product outside the PDE5-inhibitor category.
This distinction is useful when comparing labels from different products because one source may emphasize sildenafil citrate in the description while another refers simply to sildenafil in clinical pharmacology. The broader drug identity is introduced on the what is sildenafil page.
| Term | Drug Class |
|---|---|
| Sildenafil | PDE5 inhibitor |
| Sildenafil citrate | Citrate salt containing the same PDE5-inhibitor active moiety |
Brand names and salt names identify different aspects of a medicine. Sildenafil citrate describes chemical drug-substance form, whereas a proprietary name such as Viagra identifies a particular regulated medicine product.
A branded product can therefore contain sildenafil citrate while presenting its strength in terms of sildenafil. The brand does not replace the active-drug or salt-form identity; all three labels can appear at different levels of the same product description.
The relationship between sildenafil and the Viagra brand is explained separately on the sildenafil and Viagra page.
| Name Type | Example |
|---|---|
| Active-drug name | Sildenafil |
| Salt-form name | Sildenafil citrate |
| Brand name | Viagra |
Generic sildenafil products can use sildenafil citrate as the pharmaceutical drug substance while being identified commercially and clinically by the established sildenafil name. Current generic tablet labeling commonly describes sildenafil citrate as the ingredient but states that the tablets are equivalent to a specified strength of sildenafil.
The word generic addresses product and regulatory identity, whereas citrate addresses chemical salt form. A medicine can therefore be both a generic sildenafil product and a sildenafil-citrate-containing pharmaceutical product without any contradiction.
These concepts answer separate questions: generic tells the reader about product identity relative to an established reference drug, while sildenafil citrate tells the reader about the form of the drug substance.
| Concept | Question It Answers |
|---|---|
| Generic sildenafil | What type of drug product is being identified? |
| Sildenafil citrate | In what salt form is the sildenafil drug substance present? |
| Sildenafil | What is the active drug moiety? |
A salt form describes chemical identity at the drug-substance level, while a dosage form describes the physical medicine supplied for administration. These terms therefore answer fundamentally different pharmaceutical questions.
Sildenafil citrate can be used as the drug substance in tablets and oral-suspension products, and sildenafil products also exist in other administration contexts. A tablet is not a 'salt form,' just as citrate is not a synonym for tablet, liquid or injection.
Keeping these levels separate prevents a common terminology error in which chemical form and physical formulation are treated as interchangeable. The dosage-form landscape is covered on the sildenafil formulations page.
| Concept | Example |
|---|---|
| Active drug | Sildenafil |
| Salt form | Sildenafil citrate |
| Dosage form | Tablet, suspension or injection context |
The word citrate does not identify a medicine's strength. It identifies the salt form of the drug substance, whereas strength describes the amount of active drug represented in a unit of the finished medicine or in a specified concentration.
This difference is visible directly in sildenafil labeling. A tablet can contain sildenafil citrate while being designated by a sildenafil-equivalent strength, and an oral liquid can likewise be labeled according to the amount of sildenafil represented per unit volume.
Salt name, dosage form and strength should therefore be read as separate fields of product information. Confusing them can lead to incorrect comparisons of products that actually express the same active-moiety amount in different pharmaceutical forms.
| Property | What It Describes |
|---|---|
| Citrate | Chemical salt form |
| Strength | Amount of sildenafil represented in a dosage unit or concentration |
| Dosage form | Physical form in which the medicine is supplied |
No. The citrate component in sildenafil citrate should not be interpreted as a second therapeutic active ingredient alongside sildenafil. It participates in formation of the pharmaceutical salt rather than supplying an additional PDE5-inhibitor action.
This distinction matters because ingredient lists can use chemical terminology that looks more complex than the clinical drug name. Seeing sildenafil citrate on a product description does not mean that sildenafil and citrate are two separately dosed therapeutic agents.
The clinically relevant pharmacological identity remains sildenafil. Citrate belongs to the chemical description of the drug substance and should be interpreted at that level.
| Component | Interpretation |
|---|---|
| Sildenafil | Active pharmacological moiety |
| Citrate | Salt-form counterion |
| Two separate therapeutic actives? | No |
Different sources choose terminology according to what they are describing. A general medical discussion usually refers to sildenafil because the active drug and its pharmacology are the subject of interest, while manufacturing or chemical descriptions may use the full term sildenafil citrate.
Regulatory labels can legitimately use both. Description and ingredient sections may specify sildenafil citrate, whereas strengths, pharmacokinetic measurements and clinical discussions can be expressed in terms of sildenafil.
A difference in wording therefore does not automatically indicate a different medicine. The reader should first determine whether the source is describing active-drug identity, salt chemistry, product strength or finished-product formulation. The broader vocabulary used around the drug is organized on the sildenafil terminology page.
| Source Context | Likely Emphasis |
|---|---|
| General medical information | Sildenafil |
| Drug-substance chemistry | Sildenafil citrate |
| Product labeling | May use both depending on the section |
| Strength statement | Often expressed as equivalent sildenafil amount |
A common misconception is that sildenafil citrate is a stronger, weaker or fundamentally different therapeutic medicine from sildenafil. In reality, the phrase specifies the citrate salt containing the same pharmacologically relevant sildenafil moiety.
Another source of confusion is mass. Because the complete citrate salt includes more material than the sildenafil portion alone, raw salt mass and sildenafil-equivalent mass are different values. Product labels resolve this by explicitly stating the represented sildenafil strength.
A third confusion is assuming that salt form, formulation and brand are interchangeable terms. They describe different layers of the product: sildenafil is the active drug, citrate identifies the salt form, tablet or suspension identifies dosage form, and a proprietary name identifies a particular commercial product.
| Misunderstanding | Clarification |
|---|---|
| Sildenafil citrate is a different therapeutic drug | No; it is the citrate salt containing sildenafil. |
| Citrate means a different PDE5 mechanism | No; PDE5 inhibition is attributable to sildenafil. |
| Salt form and dosage form mean the same thing | No; one describes chemistry and the other physical formulation. |
| Salt mass and sildenafil-moiety mass are the same | No; labels express the corresponding sildenafil amount. |
The simplest interpretation starts with sildenafil as the active drug and citrate as the counterion that forms its pharmaceutical salt. Sildenafil citrate is therefore a chemical description of the drug substance rather than the name of a separate therapeutic agent.
Current product descriptions give this terminology a concrete context: sildenafil citrate has a reported molecular weight of approximately 666.7, while finished-product strengths are commonly stated as the amount of sildenafil to which the citrate salt is equivalent.
When reading a label, the key is to identify which level is being described: active moiety, salt form, dosage form, strength or brand. The terminology can change between sections without implying a change in the underlying sildenafil pharmacology.
| Question | Answer |
|---|---|
| What is the active drug? | Sildenafil |
| What does citrate describe? | The counterion and resulting salt form |
| Is citrate a separate therapeutic active ingredient? | No |
| Does sildenafil citrate have a separate PDE5 mechanism? | No |
| Can salt form affect pharmaceutical properties? | Yes |
| Can labels use both sildenafil and sildenafil citrate? | Yes |
Sildenafil citrate is the citrate salt form containing the active sildenafil moiety. Sildenafil provides the characteristic PDE5-inhibitor pharmacology, while citrate is the counterion in the pharmaceutical salt.
They describe different levels of the same drug substance. Sildenafil identifies the active drug moiety, while sildenafil citrate specifies the citrate salt form in which sildenafil is present.
No. Citrate does not create a separate therapeutic drug or PDE5 mechanism. Salt form can influence pharmaceutical and physicochemical properties, but the core pharmacological activity remains attributable to sildenafil.
No. Citrate serves as the counterion in the salt form rather than as a second therapeutic active ingredient.
The complete citrate salt includes both sildenafil and citrate and therefore has a different total mass from sildenafil alone. Labels express product strength in terms of the corresponding amount of active sildenafil.
Current product descriptions report a molecular weight of approximately 666.7 for sildenafil citrate. This refers to the complete citrate salt rather than to the sildenafil moiety alone.